Medicare Coverage for Specialty Drugs: Biologics, Biosimilars, and How to Manage High Costs

Specialty drugs, the high-cost biologics, targeted therapies, and injectable medications used to treat conditions like rheumatoid arthritis, multiple sclerosis, Crohn's disease, cancer, and rare conditions, represent a growing share of medication spending for Medicare beneficiaries. These drugs can cost $5,000 to $30,000 per month before insurance. Understanding how Medicare Part D covers them, what the $2,000 out-of-pocket cap means for specialty drug users in 2025, how biosimilars may reduce costs, and what assistance programs exist can make specialty drug coverage manageable rather than financially catastrophic.

Bryce's Take

The $2,000 Part D cap starting in 2025 was a genuine game-changer for my clients on expensive biologics and oral cancer drugs. I had clients paying $5,000 or more per year out of pocket. The cap does not change what drugs cost overall, but it limits how much of that cost lands on you. If you are on a specialty drug, make sure you know your plan's specific formulary placement for that drug, it varies enormously between plans.

How specialty drugs are covered under Part D

Most Part D plans place specialty drugs on Tier 5 of their formulary, the highest cost tier. Tier 5 drugs are typically subject to coinsurance, a percentage of the drug's cost rather than a flat copay. Before the Inflation Reduction Act changes, a 25% to 33% coinsurance on a $10,000 drug meant $2,500 to $3,300 per month out of pocket. Starting in 2025, the annual Part D out-of-pocket cap of $2,000 changes this dramatically. Regardless of how expensive your specialty drugs are, your total Part D cost-sharing cannot exceed $2,000 per year.

The 2025 $2,000 cap and what it means

The Part D $2,000 annual out-of-pocket cap is the most significant change to specialty drug costs for Medicare beneficiaries in decades. Once you have paid $2,000 in covered drug cost-sharing in a plan year, you pay nothing for the rest of the year regardless of what medications you take. For beneficiaries on expensive specialty drugs who previously reached the catastrophic coverage threshold with significant remaining cost exposure, the 2025 cap represents thousands of dollars in annual savings. The cap applies to all Part D covered drugs combined, not per drug.

Biosimilars and their role in reducing costs

Biosimilars are FDA-approved biological medications that are highly similar to existing biologic reference products and have no clinically meaningful differences in terms of safety or effectiveness. They are typically priced lower than the reference biologic and are increasingly available for drugs used to treat rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and cancer. Medicare Part D plans often place biosimilars on lower formulary tiers than the reference biologic, which can significantly reduce cost-sharing. Ask your prescribing physician whether a biosimilar is clinically appropriate for your condition.

Prior authorization for specialty drugs

Specialty drugs frequently require prior authorization under Part D and Medicare Advantage plans. Prior authorization for specialty drugs may require documentation of diagnosis, failed trial of alternative medications, laboratory values, or other clinical criteria. The prior authorization process can delay initiation of therapy. Starting the PA process before the drug is needed, having your physician prepare thorough documentation, and understanding your appeal rights if denied are all important steps for patients on specialty medications.

Patient assistance programs and foundations

Pharmaceutical manufacturers offer Patient Assistance Programs for uninsured or underinsured patients, but Medicare beneficiaries typically cannot use manufacturer coupons or co-pay cards under federal law. However, independent foundations, including the Patient Advocate Foundation, the HealthWell Foundation, the PAN Foundation, and disease-specific organizations, provide assistance to Medicare beneficiaries for specialty drug costs. These foundations are disease-specific and have income eligibility requirements. Applying early in the benefit year before funding is exhausted is important, as many disease foundations run out of funds.

Medicare Extra Help for specialty drugs

Beneficiaries who qualify for Medicare Extra Help receive capped copays for specialty drugs, protecting them from the high cost-sharing that would otherwise apply to Tier 5 drugs. Extra Help caps copays at $11.20 for brand-name drugs including specialty drugs in 2025. For Extra Help-eligible beneficiaries on expensive biologics, this cap is life-changing relative to the alternative cost-sharing. If your income is at or below approximately 150% of the federal poverty level, Extra Help is worth applying for.

Bryce Casson

Licensed Independent Medicare Broker

Bryce Casson is an independent Medicare insurance broker who works with every major carrier. He does not represent any single insurer, which means his recommendations are based on what actually fits each client's situation, not on commissions or quotas.